*Z:\CCTU\11. STUDY FILES\CCTU0313 - TACTIC-E\TACTIC E_Blue strapline.tif*

*Date*

Dear Dr *Name,*

Re: Participant name:

Date of Birth:

Hospital Number:

Address:

***RE:* mulTi-Arm therapeutiC sTudy in pre-Icu patients admitted with Covid-19 – Experimental drugs and mechanisms (TACTIC-E)**

***Your patient was randomised to: UNI911***

I am writing to inform you that your patient has agreed to participate in the above clinical trial at Addenbrooke’s Hospital CUH NHS FoundationTrust.

TACTIC-E is a multicentre, randomised, parallel arm, open-label platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust. The aim of the study is to test the hypotheses that:

1. Immune modulatory therapy is superior to standard of care alone (in that reduction of exaggerated host immune response to COVID-19 in patients at late stage 1/early stage 2 disease, reduces the composite of progression of these patients to organ failure or death);
2. Combination therapy with SGLT-2 and Endothelin Antagonism is superior to standard of care alone (in that antagonism of these pathways in patients at late stage 1/early stage 2 disease, reduces the composite of progression of these patients to organ failure or death);
3. Antiviral therapy with UNI911 reduces the composite of progression of these patients to organ failure or death.

More specifically, this study is evaluating the efficacy of the interventions of EDP 1815, the combination therapy of Ambrisentan and Dapagliflozin taken together or UNI911 inhalation compared to standard of care treatment.

**Your patient has been selected for the UNI911 arm.**

UNI911 is a new (unlicenced) formulation of Niclosamide allowing its administration through inhalation and nasal spraying. Niclosamide is a repurposed anti-helmithic oral drug that has been used for many years. Niclosamide has broad-spectrum antiviral effects, including potent activity against SARS-CoV-2. The treatment regimen will be combined of a nebulized pulmonary dose and an intranasal dose administered twice daily for up to 14 days.

For further information on the study,I have enclosed a copy of the Participant Information Sheet for your reference, however, if you have any queries or require further information please contact the study team:

Telephone:

Principal Investigator (PI): Dr Edward Banham-hall

Tel: +44 (0) 1223 348320/349009

Chief Investigator (CI): Dr Joseph Cheriyan

Tel: +44 (0) 1223 256653

Research Nurse: Annette Hubsch/Jo Helmy

Tel: +44 (0) 1223 586852

Patient Advice and Liaison Service (PALS) at Addenbrooke’s Hospital:

Tel: +44 (0)1223 256170, email: pals@addenbrookes.nhs.uk

**In the event of an emergency please call:**

Tel: +44(0)1223 926008 / +44(0)1223 245 151 157864

(Occasionally this may be answered by an alternative trial doctor)

Should you have any concerns about your patient participating in the study, please feel free to contact a member of the study team

Yours Sincerely,

Dr Edward Banham-Hall

**Study Team Contact Information:**

Dr Edward Banham-Hall

Addenbrooke’s Hospital

Principal Investigator

Telephone number: +44(0)1223 348320/349009

Encs: Participant Information Sheet, version 3.0 dated 03 March 2021